文献速递介入腹部MRCT

90Y经动脉放射性栓塞治疗肝脏肿瘤后的预期与意外影像学表现

Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors.
PubMed 文献 · Radiographics · 2019-01-01

本文阐述90Y经动脉放射性栓塞(TARE)治疗肝脏肿瘤后的影像学表现。治疗计划需在肿瘤杀伤剂量与正常肝、肺安全剂量间平衡;TARE后肿瘤反应可能需数月才显现,理想反应为治疗后3-6个月病灶缩小和强化减低。随访中需识别与操作相关的影像表现(瘤周水肿、炎症、环形强化、肝纤维化、包膜回缩)及可能并发症(胆管损伤、肝脓肿、放射性栓塞诱导肝病、放射性肺炎或皮炎),以正确解读影像和评估疗效。

要点

  • TARE后理想肿瘤反应为治疗后3-6个月病灶缩小和强化减低,反应显现可能需数月。
  • 评估疗效需综合考虑治疗区大小、肿瘤坏死、血供中断及功能MRI变化。
  • 随访可见瘤周水肿、炎症、环形强化、肝纤维化、包膜回缩等操作相关表现。

核心结论

  • 正确理解TARE后可能出现的治疗相关影像表现和并发症,对随访中正确解读影像和评估疗效至关重要。

研究设计与样本

  • 本文为综述,阐述90Y经动脉放射性栓塞治疗肝脏肿瘤后的预期与意外影像学表现。

关键影像表现/征象

  • TARE后随访可见瘤周水肿、炎症、环形强化、肝纤维化和包膜回缩等操作相关影像表现。
  • 理想治疗反应表现为治疗后3-6个月病灶缩小和强化减低。
  • 评估治疗反应需考虑治疗区大小、肿瘤坏死、血供中断和功能MRI变化。
  • 可能并发症包括胆管损伤、肝脓肿、放射性栓塞诱导肝病以及放射性肺炎或皮炎。

诊断标准与关键数值

  • 理想治疗反应:治疗后3-6个月病灶缩小和强化减低。
  • 评估治疗反应需综合考虑治疗区大小、肿瘤坏死、血供中断及功能MRI变化。

临床应用与阅片要点

  • 随访阅片需识别瘤周水肿、炎症、环形强化、肝纤维化和包膜回缩等治疗后改变,避免误判为进展。
  • 评估疗效时需注意TARE后肿瘤反应可能需数月才显现,理想反应在3-6个月出现病灶缩小和强化减低。
  • 需警惕胆管损伤、肝脓肿、放射性栓塞诱导肝病以及放射性肺炎或皮炎等肝内或肝外并发症。
  • 评估治疗反应时应综合治疗区大小、肿瘤坏死、血供中断和功能MRI变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Transarterial radioembolization (TARE), also called radioembolization or selective internal radiation therapy, is an interventional radiology technique used to treat primary liver tumors and liver metastases. The aim of this therapy is to deliver tumoricidal doses of radiation to liver tumors while selecting a safe radiation dose limit for nontumoral liver and lung tissue. Hence, correct treatment planning is essential to obtaining good results. However, this treatment invariably results in some degree of irradiation of normal liver parenchyma, inducing different radiologic findings that may affect follow-up image interpretation. When evaluating treatment response, the treated area size, tumor necrosis, devascularization, and changes seen at functional MRI must be taken into account. Unlike with other interventional procedures, with TARE, it can take several months for the tumor response to become evident. Ideally, responding lesions will show reduced size and decreased enhancement 3-6 months after treatment. In addition, during follow-up, there are many imaging findings related to the procedure itself (eg, peritumoral edema, inflammation, ring enhancement, hepatic fibrosis, and capsular retraction) that can make image interpretation and response evaluation difficult. Possible complications, either hepatic or extrahepatic, also can occur and include biliary injuries, hepatic abscess, radioembolization-induced liver disease, and radiation pneumonitis or dermatitis. A complete understanding of these possible posttreatment changes is essential for correct radiologic interpretations during the follow-up of patients who have undergone TARE. ©RSNA, 2019.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Spina JC, Hume I, Pelaez A, et al. Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors. Radiographics. 2019. PMID: 30844345. doi:10.1148/rg.2019180095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。